| Schizophrenia
Aristada & Aristada Initio vs Uzedy
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Aristada vs Uzedy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUzedy has a higher rate of injection site reactions vs Aristada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uzedy but not Aristada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aristada
Uzedy
At A Glance
IM injection
Monthly to every 2 months
Dopamine D2 partial agonist
SC injection
Every 4-8 weeks
Atypical antipsychotic
Indications
- Schizophrenia
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia 441 mg, 662 mg, or 882 mg monthly, 882 mg every 6 weeks, or 1064 mg every 2 months via IM injection into the deltoid (441 mg only) or gluteal muscle; initiate with ARISTADA INITIO 675 mg plus a single 30 mg oral aripiprazole dose, or supplement with 21 consecutive days of oral aripiprazole concomitant with the first injection.
Schizophrenia Once monthly SC injection (50 mg, 75 mg, 100 mg, or 125 mg) or once every 2 months (100 mg, 150 mg, 200 mg, or 250 mg) based on equivalent daily oral risperidone dose (2-5 mg); initiate the day after last oral dose, no loading dose required.
Bipolar I disorder Once monthly SC injection (50 mg, 75 mg, or 100 mg) as monotherapy or adjunctive therapy to lithium or valproate, based on equivalent daily oral risperidone dose (2-4 mg); once every 2 months dosing is not recommended for this indication.
Contraindications
- Known hypersensitivity reaction to aripiprazole (reactions have ranged from pruritus/urticaria to anaphylaxis)
- Known hypersensitivity to risperidone, its metabolite paliperidone, or any of its components
Adverse Reactions
Most common (>=5%) Akathisia
Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, leukopenia, neutropenia, agranulocytosis, seizures, orthostatic hypotension
Postmarketing Anaphylactic reaction, angioedema, pathological gambling, drug reaction with eosinophilia and systemic symptoms (DRESS), oculogyric crisis, fecal incontinence
Most common (>5%) Parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, pharyngolaryngeal pain
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinemia, orthostatic hypotension and syncope, leukopenia, neutropenia, agranulocytosis, seizures, dysphagia, priapism
Postmarketing Alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, diabetic ketoacidosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, sudden death, thrombocytopenia, injection site pain
Pharmacology
Aripiprazole lauroxil is a prodrug of aripiprazole that, following IM injection, undergoes enzyme-mediated hydrolysis to yield aripiprazole, which exerts its effects through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.
Risperidone is an atypical antipsychotic whose therapeutic activity may be mediated through combined dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism; clinical effect results from the combined concentrations of risperidone and its major active metabolite, 9-hydroxyrisperidone (paliperidone).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aristada
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Uzedy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Aristada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uzedy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aristada
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Uzedy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Aristada Co-pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Movement Disorders - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AristadaView full Aristada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.